About KELIX bio
KELIX bio is a Healthcare company based in Dubai (United Arab Emirates) founded in 2020 by Alhadi Alwazir, and was acquired by Mubadala in March 2024. Drug manufacturing for multiple therapeutic areas is pursued through RD. KELIX bio has raised $150 million across 3 funding rounds from investors including Mubadala, DPI and British International Investment. KELIX bio has completed 1 acquisition, including Pharmaceutical Institute. Its focus areas include Diversified Pharmaceuticals.
Company details
KELIX bio was established in 2020 and is headquartered in Dubai, United Arab Emirates. Research and development efforts are directed toward the production of pharmaceuticals across various therapeutic domains. Operations in the biotechnology sector emphasize drug manufacturing processes. The company was co-founded by Alhadi Alwazir, with activities centered on advancing therapeutic solutions in this field.
- Headquarters Dubai, United Arab Emirates
- Founders Alhadi Alwazir
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website kelixbio.com
- Social LinkedIn
- Acquired by Mubadala (Mar 2024)
Funding Insights of KELIX bio
KELIX bio has successfully raised a total of $150M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $150M
- Total Rounds 3
- First Round $100M
(Jun 2020)
- Investors Count 2
All 3 funding rounds of KELIX bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2022 | Series D | β | Development Partners International | β | |
| Jan 2022 | $50M | Series C | β | β | |
| Jun 2020 | $100M | Series C | β | β |
3 investors in total: 3 institutional.
Investors in KELIX bio
KELIX bio has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Mubadala, DPI and British International Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A premier African investment firm focused on high-growth businesses. | 2007 | dpi-llp.com | London, United Kingdom | |
| bii.co.uk | ||||
Sovereign wealth fund of United Arab Emirates | 2002 | mubadala.com | Abu Dhabi, United Arab Emirates |
Investor details for KELIX bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of KELIX bio
1 people are tracked at KELIX bio (1 in leadership).
| Name | Role | Group |
|---|---|---|
Alhadi Alwazir | Co-Founder | Leadership |
Complete people profiles for KELIX bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by KELIX bio
KELIX bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Pharmaceutical Institute.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Pharmaceutical Institute is engaged in producing generic medicines in Morocco. | phi.ma | Rabat, Morocco | 1988 | Mar 2022 | β’β’β’β’ |
Complete acquisition details for KELIX bio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of KELIX bio
5 dated milestones of KELIX bio across 4 years, from founding to its latest funding, stage changes and deals.
- Founded KELIX bio is founded.
- Funding First funding round of $100.0M.
- Acquisition Acquires Pharmaceutical Institute.
- Funding Latest funding round, Series D,.
- Exit Acquired by Mubadala.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kelix Bio
Complete news archive for KELIX bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about KELIX bio
KELIX bio was founded in 2020.
KELIX bio is headquartered in Dubai, United Arab Emirates. It is registered at Dubai, Dubai, United Arab Emirates.
KELIX bio is a funded company, having raised a total of $150M across 3 funding rounds to date. The company's 1st funding round was a Series C of $100M, raised on Jun 2020.
KELIX bio was established in 2020 and is headquartered in Dubai, United Arab Emirates. Research and development efforts are directed toward the production of pharmaceuticals across various therapeutic domains. Operations in the biotechnology sector emphasize drug manufacturing processes. The company was co-founded by Alhadi Alwazir, with activities centered on advancing therapeutic solutions in this field.
KELIX bio has made 1 acquisition, including Pharmaceutical Institute.
Yes. KELIX bio was acquired by Mubadala in March 2024.

